JP2023544716A5 - - Google Patents

Info

Publication number
JP2023544716A5
JP2023544716A5 JP2023519608A JP2023519608A JP2023544716A5 JP 2023544716 A5 JP2023544716 A5 JP 2023544716A5 JP 2023519608 A JP2023519608 A JP 2023519608A JP 2023519608 A JP2023519608 A JP 2023519608A JP 2023544716 A5 JP2023544716 A5 JP 2023544716A5
Authority
JP
Japan
Application number
JP2023519608A
Other languages
Japanese (ja)
Other versions
JP2023544716A (ja
JP7752684B2 (ja
JPWO2022069509A5 (https=
Filing date
Publication date
Priority claimed from EP20382861.1A external-priority patent/EP3978487A1/en
Application filed filed Critical
Publication of JP2023544716A publication Critical patent/JP2023544716A/ja
Publication of JP2023544716A5 publication Critical patent/JP2023544716A5/ja
Publication of JPWO2022069509A5 publication Critical patent/JPWO2022069509A5/ja
Application granted granted Critical
Publication of JP7752684B2 publication Critical patent/JP7752684B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2023519608A 2020-09-30 2021-09-29 トランスフォーミング増殖因子-β受容体I/ALK5の阻害剤としての2-(3-ピリジン-2-イル-4-キノリン-4-イル-ピラゾール-1-イル)-アセタミド誘導体 Active JP7752684B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20382861.1 2020-09-30
EP20382861.1A EP3978487A1 (en) 2020-09-30 2020-09-30 2-(3-pyridin-2-yl-4-quinolin-4-yl-pyrazol-1-yl)-acetamide derivatives as inhibitors of transforming growth factor-beta receptor i/alk5
PCT/EP2021/076730 WO2022069509A1 (en) 2020-09-30 2021-09-29 2-(3-pyridin-2-yl-4-quinolin-4-yl-pyrazol-1-yl)-acetamide derivatives as inhibitors of transforming growth factor-beta receptor i/alk5

Publications (4)

Publication Number Publication Date
JP2023544716A JP2023544716A (ja) 2023-10-25
JP2023544716A5 true JP2023544716A5 (https=) 2024-10-08
JPWO2022069509A5 JPWO2022069509A5 (https=) 2024-10-08
JP7752684B2 JP7752684B2 (ja) 2025-10-10

Family

ID=72744716

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023519608A Active JP7752684B2 (ja) 2020-09-30 2021-09-29 トランスフォーミング増殖因子-β受容体I/ALK5の阻害剤としての2-(3-ピリジン-2-イル-4-キノリン-4-イル-ピラゾール-1-イル)-アセタミド誘導体

Country Status (14)

Country Link
US (1) US12577230B2 (https=)
EP (2) EP3978487A1 (https=)
JP (1) JP7752684B2 (https=)
KR (1) KR20230079027A (https=)
CN (1) CN116323601A (https=)
AR (1) AR123543A1 (https=)
AU (1) AU2021353965A1 (https=)
BR (1) BR112023004612A2 (https=)
CA (1) CA3196108A1 (https=)
ES (1) ES3029607T1 (https=)
IL (1) IL301663B1 (https=)
MX (1) MX2023002900A (https=)
PH (1) PH12023550777A1 (https=)
WO (1) WO2022069509A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4065572A1 (en) 2019-11-28 2022-10-05 Origo Biopharma, S.L. Benzylamide derivatives as inhibitors of transforming growth factor-beta receptor i/alk5
WO2026017797A1 (en) 2024-07-17 2026-01-22 Agomab Spain S.L.U. Crystalline forms
CN121554469B (zh) * 2026-01-23 2026-04-17 四川大学华西医院 一种alk5 protac化合物及其应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6514977B1 (en) * 1997-05-22 2003-02-04 G.D. Searle & Company Substituted pyrazoles as p38 kinase inhibitors
PL337020A1 (en) * 1997-05-22 2000-07-31 Searle & Co Substituted pyrazoles as kinase p38 inhibitors
JP2004521915A (ja) * 2001-02-02 2004-07-22 グラクソ グループ リミテッド Tgf過剰発現に対するピラゾール誘導体
HRP20050247A2 (en) 2002-09-18 2005-10-31 Pfizer Products Inc. Pyrazole derivatives as transforming growth factor (tgf) inhibitors
WO2004026302A1 (en) 2002-09-19 2004-04-01 Eli Lilly And Company Methods of inhibiting tgf beta with substituted pyrazoles
CL2004000234A1 (es) 2003-02-12 2005-04-15 Biogen Idec Inc Compuestos derivados 3-(piridin-2-il)-4-heteroaril-pirazol sustituidos, antagonistas de aik5 y/o aik4; composicion farmaceutica y uso del compuesto en el tratamiento de desordenes fibroticos como esclerodermia, lupus nefritico, cicatrizacion de herid
WO2007005951A2 (en) * 2005-07-05 2007-01-11 Aryx Therapeutics, Inc. Stereoisomeric pyridyl and pyridonyl compounds and methods for the treatment of gastrointestinal and central nervous system disorders
CN102056907B (zh) * 2008-04-04 2014-12-31 武田药品工业株式会社 杂环衍生物及其用途
US8937150B2 (en) 2009-06-11 2015-01-20 Abbvie Inc. Anti-viral compounds
AR079545A1 (es) 2009-12-21 2012-02-01 Bayer Cropscience Ag Tienilpiri(mi)dinilazol
DK2731949T3 (en) * 2011-07-13 2018-06-14 Tiumbio Co Ltd 2-PYRIDYL-SUBSTITUTED IMIDAZOLS AS ALK5 AND / OR ALK4 INHIBITORS
ES2579832T3 (es) 2011-10-14 2016-08-17 Bristol-Myers Squibb Company Compuestos de tetrahidroisoquinolina sustituida como inhibidores del factor XIa
WO2016172631A2 (en) 2015-04-24 2016-10-27 President And Fellows Of Harvard College Substrate selective inhibitors of insulin-degrading enzyme (ide) and uses thereof
JP2021518855A (ja) 2018-03-02 2021-08-05 ユニヴェルシテ ド ローザンヌ Wntシグナル伝達経路阻害剤としてのピラゾール誘導体
US11945803B2 (en) 2018-08-07 2024-04-02 Tosk, Inc. Modulators of RAS GTPase
CN110433164A (zh) 2019-08-15 2019-11-12 南开大学 TGF-beta受体分子抑制剂在治疗小鼠动物模型中急性髓系白血病的应用
EP4065572A1 (en) 2019-11-28 2022-10-05 Origo Biopharma, S.L. Benzylamide derivatives as inhibitors of transforming growth factor-beta receptor i/alk5

Similar Documents

Publication Publication Date Title
BR112023005462A2 (https=)
BR112023012656A2 (https=)
BR112021014123A2 (https=)
BR112023009656A2 (https=)
BR112022009896A2 (https=)
JP2023544716A5 (https=)
BR112021017747A2 (https=)
BR112022024743A2 (https=)
BR112022026905A2 (https=)
JP2023504795A5 (https=)
BR112023011738A2 (https=)
BR112023004146A2 (https=)
BR112023006729A2 (https=)
BR102021018859A2 (https=)
BR102021015500A2 (https=)
BR112023016292A2 (https=)
BR112023011610A2 (https=)
BR112023011539A2 (https=)
BR112023008976A2 (https=)
BR102021020147A2 (https=)
BR102021018926A2 (https=)
BR102021018167A2 (https=)
BR102021017576A2 (https=)
BR102021016837A2 (https=)
BR102021016551A2 (https=)